[Control of tumor-related angiogenesis].
Tumor-related angiogenes is expected to become an important target for improving treatment of cancer, because it plays key roles in tumor growth, invasion and metastasis. We considered that the successful development of such angiostatic treatment depended entirely upon the development of useful anti-angiogenic agents, and attempted to find novel angiogenesis inhibitors by using three in vivo assays, based on an idea of ours. As a result we have demonstrated that different types of agents with low molecular weight including microbial metabolites, cell differentiation modulators like retinoids and steroids, exhibit anti-angiogenic activity, anti-metastatic activity and/or antitumor activity. Taken these findings, an ideal anti-angiogenic agent is discussed.
Oikawa
T
T
Department of Cancer Therapeutics, Tokyo Metropolitan Institute of Medical Science (Rinshoken), Japan. oikawa@rinshoken.or.jp
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001565:Benzoates / Q000494:pharmacology / Q000627:therapeutic use; D001688:Biological Products / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000473:pathology*; D009928:Organ Specificity; D011374:Progesterone / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D014297:Trimethylsilyl Compounds / Q000494:pharmacology / Q000627:therapeutic use
C105228:17-acetoxy-9-fluoro-6-methylprogesterone; D000970:Antineoplastic Agents; D001565:Benzoates; D001688:Biological Products; C112689:TAC 101; D014297:Trimethylsilyl Compounds; D011374:Progesterone